Mark Gardner

Mar 31, 2016

OmniSeq has appointed Mark Gardner as its CEO and as a member of its board of directors. Gardner is currently vice president and general manager for Thermo Fisher Scientific's next generation clinical sequencing business. He will transition to his new role at OmniSeq in April. Prior to his work at Thermo Fisher, Gardner held senior management positions at McKinsey, GE Medical Systems, Invitrogen, and Life Technologies.

Breaking News

Bipolar Disorder Risk Loci, Pathways Uncovered in Multi-Ancestry GWAS
Leica Biosystems, Molecular Instruments Reach Deal on Immunohistochemistry Products
Roche Gets 510(k) Clearance, CLIA Waiver for Liat Triplex Point-of-Care STI Test
Abbott Q4 Diagnostics Revenues up 4 Percent, Excluding COVID-19 Tests
MRC Holland Gains IVDR Certification for Spinal Muscular Atrophy Newborn Screening Test

Mark Gardner

Bipolar Disorder Risk Loci, Pathways Uncovered in Multi-Ancestry GWAS

Leica Biosystems, Molecular Instruments Reach Deal on Immunohistochemistry Products

Roche Gets 510(k) Clearance, CLIA Waiver for Liat Triplex Point-of-Care STI Test

Abbott Q4 Diagnostics Revenues up 4 Percent, Excluding COVID-19 Tests

MRC Holland Gains IVDR Certification for Spinal Muscular Atrophy Newborn Screening Test